SOURCE: Cerecor Inc

Cerecor Inc

August 01, 2011 09:15 ET

Cerecor Announces the Appointment of Sol Barer, Ph.D. to Its Board of Directors

BALTIMORE, MD--(Marketwire - Aug 1, 2011) - Cerecor, Inc announced today that Sol Barer, Ph.D. has joined the company's Board of Directors. Dr. Barer has been the principal executive of Celgene Corporation and over the past 25 years has led Celgene to become the 3rd largest independent biotechnology company in the world and a member of the S&P500 with a current market capitalization exceeding $25 billion. Celgene was spun out of Celanese Corporation in 1986, went public in 1987 and Dr. Barer assumed the Presidency in 1993. Subsequently, he became CEO in 2006 and Chairman of the Board of Directors in 2007. He assumed the position of Executive Chairman of the Corporation in June 2010, and retired in June 2011.

"Sol brings to Cerecor a wealth of experience regarding product development, scientific and business strategy, manufacturing, marketing and the building of an international company," said Blake Paterson, M.D., the CEO of Cerecor. Gene Bauer, M.D., the Chair of Cerecor's Board of Directors, commented: "With Sol, Cerecor acquires a remarkable strategic leader who shares common values that focus on the patient and the development of therapies for diseases that have important unmet medical needs."

In addition to Drs. Barer, Bauer and Paterson, the Cerecor Board of Directors consists of Isaac Blech, John Catsimatidis, Robert Nowinski, Ph.D. and Cary Sucoff. Cerecor, Inc is unique in that the seven-member Board collectively has over 150 years of experience in the biotechnology, starting from the infancy of the industry. In recruiting Dr. Barer to the Board of Directors, Cerecor used the team of Solit Tessler & Company.

About Cerecor: Cerecor is a Maryland-based biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary site of activity is in the human brain. We are focused on translational medicine -- the accelerated transfer of discoveries from the academic laboratory to human studies of potential drugs, with the goal of rapid commercialization. Our current product opportunities are in cough, schizophrenia and cognition, developed in partnership with various laboratories and research institutes at the Johns Hopkins Medical Institutes.

Contact Information

  • Contact information:
    Cerecor Inc.
    Phone: 410-522-8707